Cough in Idiopathic Pulmonary Fibrosis Market: Epidemiology, Therapies, Companies, DelveInsight | NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, Cellular Sciences, Emphycorp

Cough in Idiopathic Pulmonary Fibrosis therapies, such as Orvepitant Maleate, Haduvio (nalbuphine ER), and others, are expected to boost the Cough in Idiopathic Pulmonary Fibrosis Market in the upcoming years.

DelveInsight has launched a new report on "Cough in Idiopathic Pulmonary Fibrosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Cough in Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Cough in Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Cough in Idiopathic Pulmonary Fibrosis market report @ https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Cough in Idiopathic Pulmonary Fibrosis Market Report:

The Cough in Idiopathic Pulmonary Fibrosis (IPF) market is expected to show steady growth from 2023 to 2034, primarily driven by the introduction of new therapies. According to DelveInsight, the United States accounted for approximately 51% of the total diagnosed prevalent cases of cough in IPF across the seven major markets (7MM). In 2022, the EU4 and the UK collectively reported around 55,000 diagnosed prevalent cases.
As of 2022, the market in the 7MM was largely composed of treatments such as neuromodulators, corticosteroids, and other immunomodulators, generating roughly USD 154 million in revenue. Looking ahead, the market size is projected to expand with the anticipated launch of novel therapies like Orvepitant Maleate and Haduvio (nalbuphine), which promise to improve treatment outcomes for IPF-related cough.
According to DelveInsight's estimates, there were approximately 148,000 diagnosed prevalent cases of cough associated with idiopathic pulmonary fibrosis (IPF) across the seven major markets (7MM) in 2022, with this number expected to rise over the forecast period.
In the United States alone, around 95,000 individuals were diagnosed with IPF in 2022, and this figure is projected to grow at a compound annual growth rate (CAGR) through 2034.
Haduvio (oral nalbuphine ER) significantly reduced 24‐hour cough frequency by ~60% in IPF patients, with robust safety data. Trevi Therapeutics plans to request an End‐of‐Phase 2 meeting with the FDA and launch a Phase 3 program in 2026
Key Cough in Idiopathic Pulmonary Fibrosis companies such as NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, Cellular Sciences, Emphycorp, and others are evaluating new drugs for Cough in Idiopathic Pulmonary Fibrosis to improve the treatment landscape.
Promising Cough in Idiopathic Pulmonary Fibrosis therapies include Orvepitant Maleate, Haduvio (nalbuphine ER), and others.

Cough in Idiopathic Pulmonary Fibrosis Overview
Chronic cough is a common and often early symptom of idiopathic pulmonary fibrosis (IPF), significantly affecting patients' quality of life. It is linked to increased psychological distress, including depression and anxiety, greater physical impairment, and advancing disease severity.
The underlying mechanisms of cough in IPF are complex and not yet fully understood. However, recent insights suggest a multifactorial origin involving disrupted mucus production and clearance, structural changes in lung tissue, and heightened cough reflex sensitivity. These factors collectively contribute to the persistence and severity of the cough, which is closely associated with health decline and disease progression in IPF patients.

Cough in Idiopathic Pulmonary Fibrosis Market Outlook

Cough is a prominent and burdensome symptom of idiopathic pulmonary fibrosis (IPF), severely impacting patients' quality of life and highlighting the urgent need for effective, symptom-specific treatments. Although therapies for IPF exist, none are specifically approved to treat the chronic cough associated with the disease.

Current management approaches either aim to suppress the cough reflex or address the underlying IPF pathology. However, commonly used agents such as dextromethorphan and opioids offer limited effectiveness and are often associated with undesirable systemic side effects. Meanwhile, approved IPF medications like pirfenidone and nintedanib primarily target disease progression, with minimal focus on cough relief.

There is a growing emphasis on the development of targeted therapies for IPF-related cough. Investigational treatments involving neuromodulators, immunomodulators, and behavioral interventions show potential, though more robust clinical data are needed to validate their efficacy.

The therapeutic market for cough in IPF was valued at approximately USD 154 million across the 7MM in 2022 and is expected to grow significantly with the anticipated approval of promising candidates such as Orvepitant Maleate and Haduvio (nalbuphine ER).

Discover how the Cough in Idiopathic Pulmonary Fibrosis market is rising in the coming years @ https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cough in Idiopathic Pulmonary Fibrosis Emerging Drugs
Orvepitant Maleate: NeRRe Therapeutics
Haduvio (nalbuphine ER): Trevi Therapeutics

Scope of the Cough in Idiopathic Pulmonary Fibrosis Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cough in Idiopathic Pulmonary Fibrosis Companies: NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, Cellular Sciences, Emphycorp, and others
Cough in Idiopathic Pulmonary Fibrosis Therapies: Orvepitant Maleate, Haduvio (nalbuphine ER), and others.
Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and Cough in Idiopathic Pulmonary Fibrosis emerging therapies
Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Cough in Idiopathic Pulmonary Fibrosis Unmet Needs, KOL's views, Analyst's views, Cough in Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

To know what's more in our Cough in Idiopathic Pulmonary Fibrosis report, visit https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Cough in Idiopathic Pulmonary Fibrosis Market Report:
The Cough in Idiopathic Pulmonary Fibrosis market report covers a descriptive overview and comprehensive insight of the Cough in Idiopathic Pulmonary Fibrosis Epidemiology and Cough in Idiopathic Pulmonary Fibrosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Cough in Idiopathic Pulmonary Fibrosis market report provides insights into the current and emerging therapies.
The Cough in Idiopathic Pulmonary Fibrosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Cough in Idiopathic Pulmonary Fibrosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cough in Idiopathic Pulmonary Fibrosis market.

Got queries? Click here to know more about the Cough in Idiopathic Pulmonary Fibrosis market Landscape https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Cough in Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance
5. Cough in Idiopathic Pulmonary Fibrosis Market Overview at a Glance
6. Cough in Idiopathic Pulmonary Fibrosis Disease Background and Overview
7. Cough in Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Cough in Idiopathic Pulmonary Fibrosis
9. Cough in Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices
10. Unmet Needs
11. Cough in Idiopathic Pulmonary Fibrosis Emerging Therapies
12. Cough in Idiopathic Pulmonary Fibrosis Market Outlook
13. Country-Wise Cough in Idiopathic Pulmonary Fibrosis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Cough in Idiopathic Pulmonary Fibrosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Cough in Idiopathic Pulmonary Fibrosis Market Outlook 2034 https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Cough in Idiopathic Pulmonary Fibrosis Pipeline Insights, DelveInsight

"Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cough in Idiopathic Pulmonary Fibrosis market. A detailed picture of the Cough in Idiopathic Pulmonary Fibrosis pipeline landscape is provided, which includes the disease overview and Cough in Idiopathic Pulmonary Fibrosis treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.